Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Licenses Rights to Cancer Dx Technology from Epigenomics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Warnex has licensed from German molecular diagnostics firm Epigenomics non-exclusive rights to the Septin9 biomarker, the firms said in a joint announcement today.

Laval, Quebec-based Warnex intends to create a laboratory-developed test for colorectal cancer incorporating the Septin9 biomarker. It plans to launch a testing service within the next few months, and it expects to be the first provider in Canada of Septin9 testing — with a "time-limited head start period of exclusivity for the Canadian market."

Epigenomics will receive undisclosed royalty payments from Warnex. The firms did not disclose further terms of the agreement.

"This agreement is an important further step in the international rollout of Septin9 testing, which is already commercially available in the US and Europe," Geert Nygaard, CEO of Epigenomics, said in a statement.

Berlin-based Epigenomics sells the CE-marked test Epi proColon, which it said is the world's first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the Septin9 biomarker.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.